A Phase 4 interventional study of Bolus hydration therapy and Continuous hydration therapy in Acute Kidney Injury Following Administration of Contrast Media, sponsored by Yunus Emre Gemici. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Yunus Emre Gemici · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Acute Kidney Injury with a site in Turkey — 21 open to participants now, 22 under way, none of them phase 3. Acute Kidney Injury · Turkey.
Among the 90 studies in Acute Kidney Injury with a site in Turkey, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 13 that started in 2024, is one of 3 in phase 4, and was the 61st registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →21 of the 90 studies in Acute Kidney Injury with a site in Turkey are open now. Recruiting first, the newest first:
Namik Kemal University · Sites in Turkey
Ages 18+
AstraZeneca · Sites in Turkey, United States, Argentina and 11 more countries
Ages 18–80
Osman Sila Aydin · Sites in Turkey
Ages 18+
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–80
Gaziosmanpasa Research and Education Hospital · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 285 is above the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 108 across the 17 interventional studies, 130 across the 73 observational. Of the 61 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 90 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Yunus Emre Gemici as lead sponsor.
Yunus Emre Gemici has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
12 of the studies in Acute Kidney Injury with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07635160Istanbul University - CerrahpasaAssessment of Renal Perfusion Using Ultrasound and Near-Infrared Spectroscopy in Patients Undergoing Minimally Invasive Abdominal Surgery | 2027-01-07 |
| NCT07918742Istanbul University - CerrahpasaDiastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy | 2027-01-31 |
| NCT07704242Medipol UniversityEarly Kidney Injury Biomarkers in Gynecologic Laparoscopic Surgery | 2027-02-01 |
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
Add all 12 to your calendar (.ics) → With an account.
Among the 90 studies in Acute Kidney Injury with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A single-center, prospective, open-label, non-inferiority randomized controlled clinical trial was conducted at the ED of a tertiary hospital. The ED staff consisted of a mix of emergency medicine specialists, emergency medicine residents, and general practitioners.
Between August 10, 2024, and March 26, 2025, patients aged 18 and over who presented to the ED with creatinine levels above the reference range (1.2 mg/dl in men and 1.1 mg/dl in women) and underwent contrast-enhanced tomography were deemed eligible for inclusion in the study.
Eligible patients were randomly allocated in a 1:1 ratio to receive either bolus hydration or continuous hydration therapy. Permuted block randomization was employed at each participating site to distribute patients, stratified by age groups (18-44, 45-59, 60-74, and 75 years and older) and gender. This study did not use blinding. Both the implementers of the intervention and the researchers evaluating the outcome measures are aware of the intervention groups.
After the patients were divided into two groups, one group received bolus hydration therapy while the other group received continuous hydration therapy.
According to the literature, individuals with an ejection fraction of less than 40% got a half-dose hydration protocol.
The IV contrast agent used in the study was iohexol, which belongs to the non-ionic low osmolar contrast agent group. 300 mgI/ml 100 ml solutions were used, and the dose was adjusted between 80 and 100 ml depending on the imaging and the patient. In the majority of patients, 100 ml of contrast was administered, with an average of 98 ml of solution given in the bolus hydration group and an average of 96 ml of solution given in the continuous hydration group.
Patients were given control forms to provide follow-up blood samples 48-72 hours later and were asked to present to the ED with the form on the specified date. To inquire about the development of dialysis needs and mortality status, patients were contacted 30 days later to gather information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the Bolus hydration therapy group, 500 ml of 0.9% saline treatment was started half an hour before the procedure and after the procedure, 1000 ml of 0.9% saline treatment was continued at a rate of 500 ml/h to be completed in 2 hours. A total of 1500 ml 0.9% saline hydration therapy was administered over 2.5 hours. According to the literature, individuals with an ejection fraction of less than 40% got a half-dose hydration protocol. In the bolus hydration group, 250 ml of treatment was administered half an hour before the procedure, and hydration was continued at a rate of 250 ml/h for 2 hours after the procedure.
Drug: Bolus hydration therapy
In the Continuous hydration therapy group, saline treatment started 2 hours before the intravenous (IV) contrast agent application at a rate of 150 ml/h, and hydration was applied for 8 more hours after the procedure at the same rate. A total of 1500 ml 0.9% saline hydration therapy was administered over 10 hours. According to the literature, individuals with an ejection fraction of less than 40% got a half-dose hydration protocol. In the continuous hydration group, 75 ml/h of hydration was administered for 2 hours before the procedure and for 8 hours after the procedure.
Drug: Continuous hydration therapy
In the Bolus hydration therapy group, 500 ml of 0.9% saline treatment was started half an hour before the procedure and after the procedure, 1000 ml of 0.9% saline treatment was continued at a rate of 500 ml/h to be completed in 2 hours. A total of 1500 ml 0.9% saline hydration therapy was administered over 2.5 hours. According to the literature, individuals with an ejection fraction of less than 40% got a half-dose hydration protocol. In the bolus hydration group, 250 ml of treatment was administered half an hour before the procedure, and hydration was continued at a rate of 250 ml/h for 2 hours after the procedure.
In the Continuous hydration therapy group, saline treatment started 2 hours before the intravenous (IV) contrast agent application at a rate of 150 ml/h, and hydration was applied for 8 more hours after the procedure at the same rate. A total of 1500 ml 0.9% saline hydration therapy was administered over 10 hours. According to the literature, individuals with an ejection fraction of less than 40% got a half-dose hydration protocol. In the continuous hydration group, 75 ml/h of hydration was administered for 2 hours before the procedure and for 8 hours after the procedure.
Rate of Participants Who Developed Contrast-Associated Acute Kidney Injury (CA-AKI)
The primary outcome of our study was the development of CA-AKI, defined as an increase in serum creatinine value by ≥25% compared to baseline or an absolute increase in serum creatinine value by ≥0.5 mg/dL within 48-72 hours after contrast administration.
Time frame: 48-72 hours after contrast administration
Rate of Participants Who Required Dialysis
Patients were contacted by phone 1 month after the procedure and asked about the development of dialysis needs within that 1-month period.
Time frame: Up to 1 month after contrast administration
All-Cause Mortality Rate
Patients were contacted by phone 1 month after the procedure and asked about the all-cause Mortality within that 1-month period.
Time frame: Up to 1 month after contrast administration
Between August 10, 2024, and March 26, 2025, patients aged 18 and over who presented to the ED with creatinine levels above the reference range (1.2 mg/dl in men and 1.1 mg/dl in women) and underwent contrast-enhanced tomography were deemed eligible for inclusion in the study.
| Milestone | Bolus Hydration Therapy | Continuous Hydration Therapy |
|---|---|---|
| Started | 143 | 142 |
| Completed | 122 | 115 |
| Not completed | 21 | 27 |
The primary outcome of our study was the development of CA-AKI, defined as an increase in serum creatinine value by ≥25% compared to baseline or an absolute increase in serum creatinine value by ≥0.5 mg/dL within 48-72 hours after contrast administration.
| Participants | Bolus Hydration Therapy | Continuous Hydration Therapy |
|---|---|---|
| Rate of Participants Who Developed Contrast-Associated Acute Kidney Injury (CA-AKI) | 6 | 2 |
Patients were contacted by phone 1 month after the procedure and asked about the development of dialysis needs within that 1-month period.
| Participants | Bolus Hydration Therapy | Continuous Hydration Therapy |
|---|---|---|
| Rate of Participants Who Required Dialysis | 0 | 0 |
Patients were contacted by phone 1 month after the procedure and asked about the all-cause Mortality within that 1-month period.
| Participants | Bolus Hydration Therapy | Continuous Hydration Therapy |
|---|---|---|
| All-Cause Mortality Rate | 10 | 10 |
Collected over Adverse events were monitored throughout the one-month follow-up period after the enrollment of the patients.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bolus Hydration Therapy | 10/131 (7.6%) | 0/131 (0%) | 2/131 (1.5%) |
| Continuous Hydration Therapy | 10/126 (7.9%) | 0/126 (0%) | 1/126 (0.8%) |
| Event | Bolus Hydration Therapy | Continuous Hydration Therapy |
|---|---|---|
| Contrast agent allergySkin and subcutaneous tissue disorders | 2/131 | 1/126 |
| Age, Continuous(year) | Bolus Hydration Therapy | Continuous Hydration Therapy | Total |
|---|---|---|---|
| Median | 72 (60 to 80) | 73 (61 to 79) | 73 (60 to 79) |
| Sex: Female, Male(Participants) | Bolus Hydration Therapy | Continuous Hydration Therapy | Total |
|---|---|---|---|
| Female | 60 | 59 | 119 |
| Male | 71 | 67 | 138 |
| Race and Ethnicity Not Collected(Participants) | Bolus Hydration Therapy | Continuous Hydration Therapy | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Bolus Hydration Therapy | Continuous Hydration Therapy | Total |
|---|---|---|---|
| Turkey | 131 | 126 | 257 |
| Clinical characteristics(Participants) | Bolus Hydration Therapy | Continuous Hydration Therapy | Total |
|---|---|---|---|
| Diabetes Mellitus | 55 | 64 | 119 |
| Hypertension | 85 | 87 | 172 |
| Heart Failure | 19 | 23 | 42 |
| Coronary Artery Disease | 42 | 33 | 75 |
| Stroke History | 12 | 11 | 23 |
| Biochemical characteristics (Creatinine, urea, glucose)(mg/dl) | Bolus Hydration Therapy | Continuous Hydration Therapy | Total |
|---|---|---|---|
| Creatinine | 1.36 (1.25 to 1.52) | 1.32 (1.24 to 1.48) | 1.34 (1.25 to 1.5) |
| Urea | 58.5 (45.4 to 77.3) | 58.7 (44.5 to 72.7) | 58.5 (45 to 75.5) |
| Glucose | 136 (109 to 180) | 139.5 (115 to 188) | 137 (114 to 182) |
| Biochemical characteristics (eGFR)(mL/min/1.73 m²) | Bolus Hydration Therapy | Continuous Hydration Therapy | Total |
|---|---|---|---|
| Median | 45.3 (37.5 to 51.7) | 45.6 (39.8 to 53) | 45.3 (38.8 to 52.3) |
| Biochemical characteristics (Hemoglobin)(g/l) | Bolus Hydration Therapy | Continuous Hydration Therapy | Total |
|---|---|---|---|
| Median | 125 (110 to 142) | 132 (115 to 142) | 128 (111 to 142) |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data will not be shared because the study involves single-center clinical data without a dedicated data-sharing infrastructure, and sharing these data may pose risks to participant privacy despite de-identification efforts.
Ran from Aug 2024 to primary completion in Mar 2025, 7 months.
Results were first posted in Oct 2026, 1 year 6 months after primary completion.
Of 46 non-industry phase 4 interventional studies under Acute Kidney Injury, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's 7 months is below that.
Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.